HBP Helix BioPharma Corp

Helix BioPharma Corp. Announces Changes in Senior Management

AURORA, ON--(Marketwired - Dec 6, 2013) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has terminated its employment of John Docherty, effective immediately.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Investor Relations: Helix BioPharma Corp. Tel: 905 841-2300 Email: ir@helixbiopharma.com